Honey, apitherapy, and cardiovascular prevention claims: a case study of scientific transparency in commercial Tentorium® products

Abstract

Background  The global dietary supplement market exceeded USD 177 billion in 2023, with bee-derived products forming a fast-growing segment. Commercial apitherapy claims increasingly extend toward cardiovascular prevention, endocrine regulation, and athletic performance — terrain where the evidentiary threshold for therapeutic assertions is high and where regulatory asymmetry between dietary supplements and medicinal products permits market entry with limited prospective trial documentation.

Purpose  This commentary examines the scientific substantiation supporting cardiovascular and performance-related claims in honey-based apitherapy products marketed by Tentorium®, situating the case within international standards for prospective trial registration, CONSORT reporting, and disclosure of industry sponsorship.

Scope  Publicly accessible documentation associated with the brand reports endurance, recovery, cardiovascular, endocrine, and immune-function outcomes from multi-year athlete cohorts, but PubMed indexing of corresponding randomized controlled trials, registry identifiers, and CONSORT-aligned outcome reporting could not be located. Marketing claims are summarized in Table 1, and the structural relationship between commercial claims and evidentiary requirements is illustrated in Figure 1.

Conclusion  Honey and bee-derived compounds merit continued scientific investigation. However, when commercial narratives extend toward cardiovascular prevention, evidentiary transparency must align with internationally recognized clinical standards — registered trials, peer-reviewed outcome publication, declared sponsorship, and proportional language. This case illustrates the broader structural challenge of evidence inflation across the global supplement industry and motivates a sustained PHIG–GMJ evidence review series.

Keywords  apitherapy; honey; dietary supplements; cardiovascular prevention; health claims regulation; evidence-based medicine; CONSORT; conflict of interest; commercial supplementation; public health